Pain crisis management in a patient with sickle cell disease during SARS‑CoV‑2 infection: A case report and literature review

• DOI: 10.3892/wasj.2022.149
• Publication Date: 2022-03-10T08:28:50Z
• Authors: Edoardo Campanella; Andrea Marino; Manuela Ceccarelli; Maria Gussio; Federica Cosentino; Vittoria Moscatt; Cristina Micali; Giuseppe Nunnari; Benedetto Celesia; Bruno Cacopardo
• Keywords: Procalcitonin; Hypoxia; Acute Pain

Patients with sickle cell disease (SCD) are more susceptible to severe coronavirus 2019 (COVID‑19) infection, in comparison the general population, due possibility that inflammatory state, along hypoxia and hypercoagulability may increase risk of developing acute SCD‑related complications. The present study reports case a 33‑year‑old female affected by SCD, who although vaccinated against COVID‑19, tested positive for SARS‑CoV‑2 developed febrile pneumonia. During hospitalization, patient complained about generalized intense pain, fever recurrence increased marker, procalcitonin haemoglobin S levels. was treated an intravenous analgesic therapeutics cocktail combination red blood manual exchange procedure broad‑spectrum antibiotic therapy, achieving rapid resolution pain improvement laboratory test results. From presented herein, it is thus suggested patients SCD COVID‑19 infection need be critically evaluated clinicians, as such develop outcomes, attributed overlap two difficult treat conditions.